Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Vilazodone
Drug ID BADD_D02456
Description Vilazodone is a novel compound with combined high affinity and selectivity for the 5-hydroxytryptamine (5-HT) transporter and 5-HT(1A) receptors[Label,A177622]. Vilazodone may also be associated with less sexual dysfunction and weight gain[A6947]. Vilazodone was given FDA approval on January 21, 2011[L6046,A177622].
Indications and Usage Vilazodone is approved for treatment of major depressive disorder.[Label,A38477,A177622]
Marketing Status approved
ATC Code N06AX24
DrugBank ID DB06684
KEGG ID D09698
MeSH ID D000069503
PubChem ID 6918314
TTD Drug ID D0X6BV
NDC Product Code Not Available
UNII S239O2OOV3
Synonyms Vilazodone Hydrochloride | Hydrochloride, Vilazodone | 2-benzofurancarboxamide, 5-(4-(4-(5-cyano-1H-indol-3-yl)butyl)-1-piperazinyl)-, hydrochloride (1:1) | Vilazodone HCl | HCl, Vilazodone | Viibryd | EMD 68843 | 68843, EMD | EMB-68843 | EMB 68843 | EMB68843 | Vilazodone | 5-(4-(4-(5-cyano-3-indolyl)butyl)-1-piperazinyl)benzofuran-2-carboxamide
Chemical Information
Molecular Formula C26H27N5O2
CAS Registry Number 163521-12-8
SMILES C1CN(CCN1CCCCC2=CNC3=C2C=C(C=C3)C#N)C4=CC5=C(C=C4)OC(=C5)C(=O)N
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Disturbance in attention19.21.02.002; 17.03.03.0010.002108%
Dizziness02.11.04.006; 24.06.02.007; 17.02.05.0030.012011%
Dry eye06.08.02.0010.000703%
Dry mouth07.06.01.0020.001789%
Dysarthria17.02.08.001; 19.19.03.0010.000862%
Dyskinesia17.01.02.0060.002875%
Euphoric mood19.04.02.0060.000703%
Eye swelling06.08.03.0030.000703%Not Available
Feeling abnormal08.01.09.0140.008369%Not Available
Feeling jittery08.01.09.0160.002492%Not Available
Female orgasmic disorder21.03.02.018; 19.08.01.0050.000703%Not Available
Flatulence07.01.04.0020.001789%
Gastrointestinal disorder07.11.01.0010.003035%Not Available
Generalised tonic-clonic seizure17.12.01.0020.000799%Not Available
Haematemesis24.07.02.011; 07.12.02.0020.000319%Not Available
Haematochezia24.07.02.012; 07.12.02.0030.000862%Not Available
Hallucination19.10.04.0030.012873%
Hallucination, auditory19.10.04.0040.003737%Not Available
Hallucination, visual19.10.04.0070.001406%Not Available
Hallucinations, mixed19.10.04.0080.000862%Not Available
Headache17.14.01.0010.013608%
Hyperhidrosis23.02.03.004; 08.01.03.0280.003769%
Hypersensitivity10.01.03.0030.004121%
Hypoaesthesia23.03.03.081; 17.02.06.0230.002747%Not Available
Hypomania19.16.02.0010.000862%Not Available
Hyponatraemia14.05.04.0020.001406%
Increased appetite14.03.01.003; 08.01.09.0270.001246%Not Available
Influenza like illness08.01.03.0100.000479%
Initial insomnia19.02.01.005; 17.15.03.0050.000703%Not Available
Injection site pain12.07.03.011; 08.02.03.0100.001086%Not Available
The 2th Page    First    Pre   2 3 4 5    Next   Last    Total 5 Pages